Next, we examined whether the blockade of TGF-β signaling could benefit the treatment of renal cell carcinoma using PFD, an approved anti-fibrotic drug by US FDA, which is proved to suppress TGF-β signaling in other cells. Here, TGFB1 is linked to hereditary clear cell renal cell carcinoma.